Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Point-of-care CAR-T in R/R CD19+ NHL and ALL
NCT06027957Phase 1Completed
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
- Start
- Aug 2023
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Anti-CD19 CAR T-cells (Beijing Doing Biomedical) in B-cell non-Hodgkin lymphoma (B-NHL) and acute lymphoblastic leukemia (ALL), sponsored by Vinmec Research Institute of Stem Cell and Gene Technology. Primary endpoint: Frequency and severity of adverse events and serious adverse events at 6 months. Started Aug 2023; status: completed.
02
Drugs
Anti-CD19 CAR T-cells (Beijing Doing Biomedical)
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06027957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027957.